Evidence map›Paper›PMID 39151917›Full record

ArticleBioconjugate chemistry2024

Click Chemistry Enables [

Ryota Imura, Jaewoong Jang, Atsuko Nakanishi Ozeki, Hiroyuki Takahashi, Hiroyuki Ida, Youichiro Wada, Yoshitaka Kumakura, Nobuyoshi Akimitsu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioconjugate chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Pharmaceutics · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ryota ImuraResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro, Tokyo 153-8904, Japan.
Jaewoong JangIsotope Science Center, The University of Tokyo, Bunkyo, Tokyo 113-0032, Japan.ORCID 0000-0002-8466-0502
Atsuko Nakanishi OzekiIsotope Science Center, The University of Tokyo, Bunkyo, Tokyo 113-0032, Japan.
Hiroyuki TakahashiInstitute of Engineering Innovation, School of Engineering, The University of Tokyo, Bunkyo, Tokyo 113-8656, Japan.
Hiroyuki IdaJFE Engineering Corporation, Yokohama, Kanagawa 230-8611, Japan.
Youichiro WadaResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro, Tokyo 153-8904, Japan.
Yoshitaka KumakuraIsotope Science Center, The University of Tokyo, Bunkyo, Tokyo 113-0032, Japan.ORCID 0000-0003-1659-765X
Nobuyoshi AkimitsuIsotope Science Center, The University of Tokyo, Bunkyo, Tokyo 113-0032, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There have been predictions that the use of the macrocyclic chelating agent 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) in zirconium-89 (

Indexed as

Click ChemistryHeterocyclic Compounds, 1-RingImmunoconjugatesPositron-Emission TomographyRadioisotopesZirconiumAnimalsAntibodies, MonoclonalCell Line, TumorHumansMiceMice, NudeRadioimmunotherapyRadiopharmaceuticalsTheranostic Nanomedicine1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidAntibodies, MonoclonalHeterocyclic Compounds, 1-RingImmunoconjugatesRadioisotopesRadiopharmaceuticalsZirconiumZirconium-89

Identifiers

PMID39151917
PMCPMC11583970

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.